Elutia(ELUT)
Search documents
Elutia Announces First Patient Implant of EluPro™, the World's First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators
GlobeNewswire News Room· 2024-09-05 20:05
SILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever patient implant of EluPro®, the world's first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA). The groundbreaking procedure was performed by John Catanzaro, MD, MBA, Chief, Division of Cardiology, Director, Cardiology Services, and Program Director of Clinical Cardiac ...
Elutia to Participate in Upcoming Investor Conferences
GlobeNewswire News Room· 2024-09-03 20:05
SILVER SPRING, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences in New York: H.C. Wainwright 26th Annual Global Investment Conference Format: Presentation and 1x1 Meetings Presentation Date and Time (On-demand beginning): Monday, September 9, 2024, 7: ...
Elutia(ELUT) - 2024 Q2 - Quarterly Report
2024-08-13 13:22
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | |--------------------------------------------------|---------------------------------------------------------------------------------------------- ...
Elutia(ELUT) - 2024 Q2 - Earnings Call Presentation
2024-08-10 11:27
2nd Quarter 2024 Financial Results Call C. Randal Mills PhD Chief Executive Officer Matt Ferguson Chief Financial Officer August 7, 2024 Forward-Looking Statements This presentation of Elutia Inc. ("Elutia," "we," "us," "our" or the "Company") (together with any other statements or information that we may make or discuss in connection herewith) contains forward-looking statements. All statements other than statements of historical facts, including but not limited to statements regarding the market potential ...
Elutia(ELUT) - 2024 Q2 - Earnings Call Transcript
2024-08-10 11:27
Elutia Inc. (NASDAQ:ELUT) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners, IR Randy Mills - President and CEO Matt Ferguson - Chief Financial Officer Conference Call Participants Matthew Park - Cantor Fitzgerald Frank Takkinen - Lake Street Capital Markets Operator Greetings. Welcome to the Elutia Second Quarter 2024 Financial Results Call. At this time, all participants are in listen-only mode. The question-and-answer session will follow the fo ...
Elutia(ELUT) - 2024 Q2 - Quarterly Results
2024-08-07 20:01
Exhibit 99.1 Elutia Announces Second Quarter 2024 Results Launch Production of EluPro Underway, Commercial Team Expansion Continues, Financial Position Solidified SILVER SPRING, Md., August 7, 2024 — Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today provided a business update and financial results for the second quarter ended June 30, 2024. Business Highlights: · Received FDA clearance for EluPro, the first antibiotic-eluting BioEnvelope for protecti ...
Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations
GlobeNewswire News Room· 2024-07-31 20:05
SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of Operations. Dr. Marques brings more than 20 years of experience leading operations teams across manufacturing, quality assurance, supply chain and technical services in the device and pharmaceutical industries. "We are pleased to welcome Ryan to the Elutia CRU as our new Vice President of Ope ...
Elutia to Present at the Emerging Growth Conference on Thursday, July 18
GlobeNewswire News Room· 2024-07-11 20:05
SILVER SPRING, Md., July 11, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the Emerging Growth Conference on Thursday, July 18, 2024, at 12:35 p.m. ET (9:35 a.m. PT). About Elutia The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment ...
Elutia to Present at the Emerging Growth Conference on Thursday, July 18
Newsfilter· 2024-07-11 20:05
SILVER SPRING, Md., July 11, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the Emerging Growth Conference on Thursday, July 18, 2024, at 12:35 p.m. ET (9:35 a.m. PT). Following the presentation, Elutia management will also participate in 1x1 investor meetings. Institutional investors interested in scheduling a meeting may contact IR@elutia.com. Elutia d ...
Elutia Announces $13.26 Million Registered Direct Offering
Newsfilter· 2024-06-17 12:01
SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company") today announced it has entered into a definitive agreement with investors for the purchase and sale of 3,175,000 shares of the Company's Class A common stock at a purchase price of $3.40 per share and 725,000 prefunded warrants to purchase up to 725,000 shares of the Company's Class A common stock at a purchase price of $3.399 per prefunded warrant in a registered direct offering. The prefunded warra ...